by Raynovich Rod | Aug 28, 2022 | 2020-21 Life Science Portfolios, Macro
Update-1 Third Day this week of flailing around in the red, even AAPL down 1%. Small cap winners: EVH,MRTX, QDEL speculative ETFs: ARKG up 1.31%, XBI up 0.72% at $83.70 IBB flat at $121.46, XLV down 0.64% at $124.76. Notable biotech movers: CYTK up 3.78% at $52.96,...
by Raynovich Rod | Oct 7, 2020 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-3 10/15 1;20P… Both the IBB and XBI are stalled at the current 2020 double top. Our new picks are holding OSUR at $14.65, PACB $14.42 and VIR at $42. 10/16 11 a BioNTech (BNTX) and Pfizer emerging as vaccine leaders.Data coming soon. ==============...
by Raynovich Rod | Nov 9, 2015 | Biopharmaceuticals
Small Caps Hot, Large Caps Not Curis (CRIS) and Fibrocell Science (FCSC) Lead the Way Up Biotech stocks could not extend last month’s rally in choppy trading that left major indices up but off mid-week highs. The healthcare sector sold off on continued pricing...
by Raynovich Rod | Jun 9, 2015 | 2023 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Updated 6/10 Biotech ETFs lag overall in 1.4% rally. Materials, financials and technology lead. Large cap biotechs doing well. Rayno portfolio winners today: ALXN, BIIB, GILD, RHHBY etc Rapid Fire Re-Balancing of ETFs into More Speculative Names Is the Tail Wagging...
by Raynovich Rod | May 6, 2013 | 2023 Rayno Biopharmaceuticals Portfolio, BIOgraph
Rayno Biopharma Portfolio We are still cautious on adding new biotech positions except stocks that were mentioned last month (see Alkermes ALKS, Array ARRY and Achillion ACHN). Many biotech MO stocks are well off their highs. All positions remain as HOLDS unless you...
by Raynovich Rod | Feb 26, 2013 | 2023 Rayno Biopharmaceuticals Portfolio, BIOgraph
Caution-Follow Technicals-Potential for Macro Risk Off The Life Science sector is about 2% off highs of February 1 and has formed a double top from October 5 highs. In recent posts we urged caution as some MO stocks had blow-off tops (ALXN,MDVN, REGN) and the IBB and...
by Raynovich Rod | Jan 16, 2013 | BIOgraph, Life Science ETF's and Mutual Funds
Biotech ETF’s Slightly Outperform Life Science Mutual Funds There has been an ongoing debate in the media on the performance of ETFs compared to actively managed funds so we have compared the performance in a hot sector like biotech which is entering its 5th...
by Raynovich Rod | Nov 16, 2011 | Biopharmaceuticals
Managed Healthcare Mutual Funds Starting To OutPerform ETFs Earlier this year we wrote an article on Investor Uprising comparing returns on biotech funds and major ETFs. At the time ETF’s were outperforming managed mutual funds. Now as we enter the strong...
by Rod Raynovich | Mar 22, 2010 | BIOgraph
Healthcare and biotech stocks were up today as expected following passage of the historic reform bill. Although there is a considerable amount of work to be done in enabling the historic legislation, uncertainty has been removed and the market can play it out. Many...
by Rod Raynovich | Mar 3, 2010 | BIOgraph
Medivation (MDVN) released disappointing Phase III results for its Alzheimer drug, known as dimebon, saying that the drug was ineffective in treating cognitive decline or behavioral disorders. The stock plunged 67% to 13 as of midday trading on Wednesday. In a joint...